NEWMAN MARY 4
4 · Audentes Therapeutics, Inc. · Filed Aug 25, 2017
Insider Transaction Report
Form 4
NEWMAN MARY
SVP, Regulatory Affairs
Transactions
- Sale
Common Stock
2017-08-24$20.00/sh−10,000$200,000→ 0 total - Exercise/Conversion
Common Stock
2017-08-24$2.19/sh+10,000$21,900→ 10,000 total - Exercise/Conversion
Stock Option (right to buy)
2017-08-24−10,000→ 43,817 totalExercise: $2.19Exp: 2025-02-04→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- [F2]The option vested as to 25% of the total shares on October 1, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on October 1, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.